US2003130332A1PendingUtilityA1

Method for prophylaxis and treatment of diabetic complications with 4[alpha-hydroxy-2-methyl-5-(1-imidazolyl)benzyl]-3,5-dimethylbenzoic acid and derivatives

51
Priority: Dec 27, 1995Filed: Jan 30, 2003Published: Jul 10, 2003
Est. expiryDec 27, 2015(expired)· nominal 20-yr term from priority
Inventors:Yoshiharu HayashiNobuharu Goto
A61P 9/00A61P 25/00A61P 3/00A61P 25/02A61P 27/00A61P 3/10A61P 13/00A61K 31/4164C07D 249/08C07D 231/12C07D 233/56C07D 233/54A61K 31/415C07D 233/60
51
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to an agent for the prophylaxis and treatment of diabetic complications comprising, as an active ingredient, 4-[α-hydroxy-2-methyl-5-(1-imidazolyl)benzyl]-3,5-dimethylbenzoic acid, an optically active compound thereof or a pharmaceutically acceptable salt thereof. The present invention further relates to a method for the prophylaxis and treatment of diabetic complications comprising administering an effective amount of this compound. The medicament of the present invention is useful for the prophylaxis and treatment of diabetic complications, namely, diabetic neuropathy, nephropathy, ophthalmopathy, arteriosclerosis and the like. The action of the drug is long-lasting for very small doses and a single administration a day is sufficient.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . A method for the prophylaxis and treatment of diabetic ophthalmopathy, comprising administering an effective amount of 4-[α-hydroxy-2-methyl-5-(1-imidazolyl)benzyl]-3,5-dimethylbenzoic acid, an optically active compound thereof or a pharmaceutically acceptable salt thereof.  
     
     
         2 . A method for the prophylaxis and treatment of diabetic ophthalmopathy, comprising administering an effective amount of sodium 4-[α-hydroxy-2-methyl-5-(1-imidazolyl)benzyl]-3,5-dimethylbenzoate dihydrate.  
     
     
         3 . A method for the prophylaxis and treatment of diabetic ophthalmopathy, comprising administering an effective amount of (S)-(−)-4-[α-hydroxy-2-methyl-5-(1-imidazolyl)benzyl]-3,5-dimethylbenzoic acid or a pharmaceutically acceptable salt thereof.  
     
     
         4 . A method for the prophylaxis and treatment of diabetic ophthalmopathy, comprising administering an effective amount of sodium (S)-(−)-4-[α-hydroxy-2-methyl-5-(1-imidazolyl)benzyl]-3,5-dimethylbenzoate ⅔ hydrate.  
     
     
         5 . A method for the prophylaxis and treatment of diabetic arteriosclerosis, comprising administering an effective amount of 4-[α-hydroxy-2-methyl-5-(1-imidazolyl)benzyl]-3,5-dimethylbenzoic acid, an optically active compound thereof or a pharmaceutically acceptable salt thereof.  
     
     
         6 . A method for the prophylaxis and treatment of diabetic arteriosclerosis, comprising administering an effective amount of sodium 4-[α-hydroxy-2-methyl-5-(1-imidazolyl)benzyl]-3,5-dimethylbenzoate dihydrate.  
     
     
         7 . A method for the prophylaxis and treatment of diabetic arteriosclerosis, comprising administering an effective amount of (S)-(−)-4-[α-hydroxy-2-methyl-5-(1-imidazolyl)benzyl]-3,5-dimethylbenzoic acid or a pharmaceutically acceptable salt thereof.  
     
     
         8 . A method for the prophylaxis and treatment of diabetic arteriosclerosis, comprising administering an effective amount of sodium (S)-(−)-4-[α-hydroxy-2-methyl-5-(1-imidazolyl)benzyl]-3,5-dimethylbenzoate ⅔ hydrate.  
     
     
         9 . The method of  claim 1 , wherein the diabetic ophthalmopathy is cataract.  
     
     
         10 . The method of  claim 1 , wherein the diabetic ophthalmopathy is glaucoma.  
     
     
         11 . The method of  claim 1 , wherein the diabetic ophthalmopathy is retinopathy.  
     
     
         12 . The method of  claim 1 , wherein the diabetic ophthalmopathy is iritis.  
     
     
         13 . The method of  claim 2 , wherein the diabetic ophthalmopathy is cataract.  
     
     
         14 . The method of  claim 2 , wherein the diabetic ophthalmopathy is glaucoma.  
     
     
         15 . The method of  claim 2 , wherein the diabetic ophthalmopathy is retinopathy.  
     
     
         16 . The method of  claim 2 , wherein the diabetic ophthalmopathy is iritis.  
     
     
         17 . The method of  claim 3 , wherein the diabetic ophthalmopathy is cataract.  
     
     
         18 . The method of  claim 3 , wherein the diabetic ophthalmopathy is glaucoma.  
     
     
         19 . The method of  claim 3 , wherein the diabetic ophthalmopathy is retinopathy.  
     
     
         20 . The method of  claim 3 , wherein the diabetic ophthalmopathy is iritis.  
     
     
         21 . The method of  claim 4 , wherein the diabetic ophthalmopathy is cataract  
     
     
         22 . The method of  claim 4 , wherein the diabetic ophthalmopathy is glaucoma.  
     
     
         23 . The method of  claim 4 , wherein the diabetic ophthalmopathy is retinopathy.  
     
     
         24 . The method of  claim 4 , wherein the diabetic ophthalmopathy is iritis.

Join the waitlist — get patent alerts

Track US2003130332A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.